Ophthalmic Business News

WAILEA, Hawaii — The Advanced Research Projects Agency for Health has launched a program to restore vision through the transplantation of whole human eyes, according to a speaker here.

WAILEA, Hawaii — In this Healio video perspective, Mark L. Baum, chairman and CEO at Harrow, discusses the launch of Vevye ophthalmic solution for the treatment of dry eye disease, here at Hawaiian Eye 2024.

The first patient has been dosed in a phase 2 clinical trial investigating EYP-1901 for the treatment of diabetic macular edema, according to a press release from EyePoint Pharmaceuticals.

The Advanced Research Projects Agency for Health has launched the Transplantation of Human Eye Allografts program, which aims to transplant whole human eyes to restore vision, according to a press release.

The FDA approved the VisuMax 800 femtosecond laser with SMILE pro software for the treatment of myopia with or without astigmatism, according to a press release from Carl Zeiss Meditec.

“Why should I be investing in bonds when I can earn more than 5% on my cash?” Many investors, including physicians, are asking this question after being discouraged by losses they have experienced with bonds in recent years.

Two pivotal phase 3 clinical trials evaluating the efficacy and safety of AR-15512 for treating the signs and symptoms of dry eye disease achieved the primary endpoint, according to a press release from Alcon.

The top Healio blogs in ophthalmology last year explored the future of drug prices in the wake of the Inflation Reduction Act and important tips for avoiding Stark Law violations.

The FDA approved the Teneo excimer laser platform for LASIK vision correction surgery for myopia and myopic astigmatism, according to a press release from Bausch + Lomb.

Harrow announced three partnerships to support the upcoming launch of Vevye, indicated for treating the signs and symptoms of dry eye disease.